Related Experiment Video
Updated: Mar 13, 2026
Modeling Brain Metastasis by Internal Carotid Artery Injection of Cancer Cells
Published on: August 2, 2022
Treatment of brain metastases in the modern genomic era
Ibiayi Dagogo-Jack1, Corey M Gill2, Daniel P Cahill3
1Department of Medicine, Massachusetts General Hospital and Harvard Medical School, Boston, MA, United States; Cancer Center, Massachusetts General Hospital and Harvard Medical School, Boston, MA, United States.
Abstract:
Development of brain metastasis (BM) portends a dismal prognosis for patients with cancer. Melanomas and carcinomas of the lung, breast, and kidney are the most common malignancies to metastasize to the brain. Recent advances in molecular genetics have enabled the identification of actionable, clinically relevant genetic alterations within primary tumors and their corresponding metastases. Adoption of genotype-guided treatment strategies for the management of systemic malignancy has resulted in dramatic and durable responses. Unfortunately, despite these therapeutic advances, central nervous system (CNS) relapses are not uncommon. Although these relapses have historically been attributed to limited blood brain barrier penetration of anti-neoplastic agents, recent work has demonstrated genetic heterogeneity such that metastatic sites, including BM, harbor relevant genetic alterations that are not present in primary tumor biopsies. This improved insight into molecular mechanisms underlying site specific recurrences can inform strategies for targeting these oncogenic drivers. Thus, development of rational, genomically guided CNS-penetrant therapies is crucial for ongoing therapeutic success.
Insights
Brain metastases (BM) are common in cancer, but genetic differences between primary tumors and BM limit treatment effectiveness. Understanding these genetic disparities is key to developing new therapies that can reach the central nervous system (CNS).
Area of Science:
- Oncology
- Molecular Genetics
- Neuro-oncology
Background:
- Brain metastasis (BM) significantly worsens cancer patient prognosis.
- Common primary cancers include melanoma, lung, breast, and kidney.
- Genetic alterations in primary tumors guide systemic cancer therapy, improving outcomes.
Purpose of the Study:
- To investigate the genetic heterogeneity between primary tumors and brain metastases.
- To understand molecular mechanisms driving site-specific recurrence in the CNS.
- To inform the development of targeted therapies for CNS relapses.
Main Methods:
- Analysis of genetic alterations in primary tumors and corresponding brain metastases.
- Comparison of genomic profiles to identify discrepancies.
- Review of current therapeutic strategies and their limitations in CNS penetration.
Main Results:
- Brain metastases harbor distinct genetic alterations not found in primary tumors.
- Genetic heterogeneity contributes to treatment challenges in the central nervous system (CNS).
- Limited blood-brain barrier penetration of therapies is a historical challenge.
Conclusions:
- Genomic-guided strategies are essential for managing systemic malignancy.
- Targeting specific oncogenic drivers in BM requires understanding genetic differences.
- Development of CNS-penetrant therapies is crucial for improving outcomes in patients with brain metastases.
Related Concept Videos
02:57Targeted Cancer Therapies
There are several types of targeted therapies against...
02:56Treatment Resistant Cancers
02:56Treatment Resistent Cancers
02:50Combination Therapies and Personalized Medicine
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...